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Abstract
Background: The DelIVery for Pulmonary Arterial Hypertension clinical trial was a multi-center, prospective, single arm,
Investigational Device Exemption study utilizing a fully implantable, programmable intravascular delivery system consisting of a
pump and a catheter for intravenous treprostinil. The study met its primary endpoint and demonstrated that the intravascular
delivery system significantly reduced catheter related complications at 22,000 subject-days of follow-up compared with a predefined objective performance criterion. Here we summarize the results obtained during a 6.4-year follow-up period.
Methods: Throughout study follow-up, participants had clinic visits and medication refills at least every 12 weeks (dependent on
the subjects’ dose). All adverse events and intravascular delivery system complications were evaluated and recorded.
Results: Sixty pulmonary arterial hypertension subjects were followed post device implantation for approximately 282 patientyears (range 87 days to 6.4 years). Of the 60 subjects, 14 died (1 related to intravascular delivery system pump failure), 2 withdrew
after lung transplants, and 2 withdrew due to pump pocket infection. No catheter-related bloodstream infections, catheter
thrombosis or occlusions, or catheter kinks occurred through 282 patient-years. Two participants had adverse events of abdominal
pain, rash, due to subcutaneous treprostinil ‘‘leaks’’ after one catheter puncture and one catheter laceration during pump refill and
replacement, respectively. Eight pump failure events occurred: seven pump motor stalls and one early replacement (faulty battery).
Conclusion: Delivery of treprostinil with an intravascular delivery system is a safe alternative to an external delivery system, while
providing enhanced life experiences. To preserve the risk–benefit ratio, treatment at specialized pulmonary arterial hypertension
centers is recommended until training is disseminated at other sites.

Keywords
pulmonary arterial hypertension, treprostinil, prostacyclin, internal device
Date received: 18 April 2019; accepted: 4 September 2019

Pulmonary Circulation 2019; 9(4) 1–9
DOI: 10.1177/2045894019878615

Introduction
Current World Symposium Proceedings in Pulmonary
Hypertension recommend treatment with parenteral prostacyclins for high-risk newly diagnosed or rapidly progressing
pulmonary arterial hypertension (PAH) requiring escalation
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of therapy.1,2 However, risks and complexities associated
with current external delivery systems limit the use of parenteral therapy.3,4 In addition, the use of prostacyclins may be
limited in part as all PAH therapies are expensive, with use
limited by individual political and geographic constraints.
The DelIVery for Pulmonary Arterial Hypertension
(PAH) clinical trial was a multi-center, prospective, single
arm, Investigational Device Exemption study utilizing a
fully implantable, programmable intravascular delivery
system (IDS) consisting of a pump and a catheter for intravenous (IV) treprostinil. An exemption study allows the
device, in this case the approved Medtronic SynchroMed
II model 8637 pump with the novel 10642 catheter designed
by Medtronic for treprostinil delivery at low ﬂow rates, to
be used in clinical study as a novel system to collect safety
and outcome data. The study met its primary endpoint and
demonstrated a reduced rate of catheter-related complications (systemic bloodstream infections, site infections, and
complications from catheter thrombosis, mechanical dysfunction, or catheter dislocation) or procedure-related
pneumothorax using the implantable system after 22,000
patient-days of implant compared with a predeﬁned objective performance criterion (OPC).5 A completely implantable
delivery system (IDS) for treprostinil infusion allowed PAH
patients to return to normal daily activities (e.g. bathing
without fear of infection and sleeping without worry of dislocating or kinking the infusion catheter), by reducing the
risks of these speciﬁc complications associated with external
delivery systems. This manuscript provides performance and
safety information, and protocol and technical adjustments
of the IDS over a 6.4-year follow-up period since the ﬁrst
patient was implanted.

Methods

follow-up visits as part of routine clinical care for patients
with advanced PAH and depending on dose at planned
pump reﬁll visits, and at unscheduled follow-up visits as
clinically indicated. During follow-up visits, the implanted
pump was reﬁlled with treprostinil via percutaneous needle
access to the pump reservoir at intervals dependent on
patient dose (up to a maximum of 12 weeks). At the time
of a reﬁll, residual drug remaining in the pump reservoir was
removed, quantiﬁed, and discarded, and the pump reﬁlled
with fresh drug (10 mg/mL concentration). In all cases the
programmed dose versus actual dose delivered was assessed
and any dose discrepancy was tracked for each subject.
In the later part of the study, the concentrated treprostinil
was chilled at approximately 4 C for at least 30 min prior to
use in reﬁll procedure to limit any leakage of drug from the
reﬁll needle.

Adverse events (AE) and IDS complications
All AEs were reported throughout the study. This excluded
documented pre-existing conditions unless the nature or
severity of the condition worsened. Serious AEs were
deﬁned as those that were life-threatening that could result
in death, hospitalization, or require intervention to prevent
a serious outcome. Catheter failures were deﬁned as events
that required replacement of the catheter. Pump failure
was deﬁned as inability to restart the pump after unplanned
cessation. Pump stall is a cessation of the pump. System
modiﬁcation is deﬁned as replacement of the catheter and/
or pump.
An independent Adverse Events Advisory Committee
(AEAC) reviewed all AEs. The AEAC and the investigators
worked with the biomedical engineers throughout the study
to determine causation of any mechanical pump or catheter
and, system related issues. All AEs were adjudicated by the
AEAC and steering committee and appropriate changes
to the study protocol were made regarding process and
clinical care.

The subject selection, design, and detailed methods of the
DelIVery for PAH trial have been previously published
including a description of the unique catheter design6 and
system implant techniques utilized in the study (model 10642
Implantable
Intravascular
Catheter,
model
8637
SynchroMed II Implantable Programmable Pump, and the
model 8840 N’Vision Clinician Programmer (Medtronic,
plc).5 A total of 10 US centers participated in this longterm observational study under an Investigational Device
Exemption in accordance with the amended Declaration
of Helsinki. The institutional review boards (IRBs) at each
center approved the protocol, and written informed consent
was obtained from all patients. The study was registered
with clinicaltrials.gov under number NCT01321073. For
full details of the participating IRBs, please see the online
supplement.

Summary statistics were reported as mean  standard deviation for continuous variables, and count (%) for categorical variables. Survivorship analysis was conducted using the
Kaplan–Meier method, with events that included death,
catheter failure, pump failure, pump replacement, and
system modiﬁcation. Subjects were censored at their last
known follow-up. Survivorship point estimates and 95%
conﬁdence intervals are provided. Comparisons were made
using Fishers exact test with p values below 0.05 considered
statistically signiﬁcant.

Implant and follow-up procedures

Results

The implant procedure has been previously published
in detail.7 Implanted subjects were seen at scheduled

Participants (n ¼ 60) were implanted from June 2011
through November 2012 and have accumulated a total of

Statistical methods
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Table 1. Baseline characteristics of implanted subjects.

Enrolled^ (n=64)

Baseline characteristics
Exited prior to implant attempt (n=4)

Received Implant (n=60)

Died (n=14)

Exited (n=2)

Transplanted (n=2)

Currently* Active (n=42)
^Between June 2011 and November 2012
*As of November 1, 2017

Fig. 1. CONSORT flow diagram.

281.8 patient-years of follow-up (mean 4.7  1.4 years; range
87 days to 6.4 years). Forty-two participants (70.0%)
remain in the study, 14 (23.3%) died, and 4 (6.7%) withdrew
(Fig. 1). The 42 participants still in the study had an average
age of 47.6 years at implant, 85.7% are female, versus the
entire study population which had an average age of 50.1
years and 80% female (Table 1). One of the 14 deaths was
adjudicated by the AEAC to be related to the investigational
system. In this case, a patient died due to disease progression after a pump failure confounded by a subsequent clinical care failure as adjudicated by the AEAC. The subject
was transferred to their study center with symptoms of worsening dyspnea. Unfortunately, the recommended study
protocol procedure for pump interrogation and assessment
in the event of worsening symptoms, and if indicated, the
subsequent initiation of treprostinil via an external pump,
was not followed. Thus, the pump failure was not detected
with subsequent death of the patient. Engineers analyzed the
pump system post-mortem and conﬁrmed pump failure.
Two subjects withdrew from the study after lung transplantation and two withdrew due to infections following
pump replacement out of the 17 total pump replacements.
Figure 2 shows the Kaplan–Meier survival curve for the
study using death from any cause as the event. The ﬁveyear post-implant survival estimate was 76.4% (95% CI:
63.3–85.3%). The rate of catheter-related complications
throughout the study was 0.08/1000 patients-days versus
the OPC of 2.5/1000 patients-days (p < 0.0001). This
includes the events previously described (5) that contributed
to the primary-endpoint occurring within the ﬁrst 22,000
patient-days (three catheter dislocations, one venous stenosis, one punctured catheter, and one pneumothorax), plus
one additional catheter puncture during pump reﬁll, and one
catheter laceration during pump replacement.

Enrolled subjects
(n ¼ 60)
Age (years)
Gender (female)
Race/Ethnic origin
Asian
Black or African American
Hispanic or Latino
White or Caucasian
Classification of PAH
Idiopathic
Heritable
Associated
Congenital heart disease
Dose of remodulin (ng/kg/min)
I
II
III
IV

50.1  13.5
48 (80.0%)
2
3
8
47

(3.3%)
(5.0%)
(13.3%)
(78.3%)

35 (58.3%)
2 (3.3%)
23 (38.3%)
4 (6.7%)
71.4  27.8
10 (17)
30 (50%)
20 (33%)
0 (0.0%)

PAH: pulmonary arterial hypertension.
Continuous variables: mean  SD. Categorical variables: count (%).

The two catheter punctures seen during the study occurred
in the same patient at diﬀerent reﬁlls. For both cases, the
patient experienced pain and a rash near the pump, and
after infection was ruled out, ﬂuoroscopy was conducted
and demonstrated that the catheter body had migrated anterior to the reﬁll port on the pump. The catheter was removed
and inspected, and it was determined that the catheter had
been punctured by the reﬁll needle. Treprostinil was being
administered subcutaneously through the hole instead of
intravenously through the catheter tip and causing pain and
erythema (known to occur with subcutaneous infusion of
treprostinil with external infusion systems). The punctures
did not result in symptoms of treprostinil over-/underdosing because the patient continued to receive the correct
dose (subcutaneously administered treprostinil is 100%
bioavailable).8 Unfortunately, after replacement of the
second punctured catheter, the patient developed an infection
and the patient exited the study (mentioned above).
The catheter laceration was discovered after the patient
had severe erythema anterior to the pump for approximately
two months despite antibiotic treatments for possible infection. The pump and catheter were explanted and upon
inspection it was determined that the catheter had been
cut by the scalpel during a routine pump replacement two
months earlier. Several months after explant, all symptoms
resolved, and the patient received a new pump and catheter.
Throughout the study, there were 17 pump replacements,
9 were routine, as device was nearing expected end of service, 8 pumps have failed in 8 (13%) patients that involved
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Fig. 2. Kaplan–Meier survivorship plot with 95% confidence limit error bars. Five-year estimate from implant to death 76.4% (95% CI 63.3–
85.3%).

Fig. 3. Scatter plot of years post-implant (x-axis) vs. estimated pump motor turns (y-axis), with pump motor stalls identified with solid circles.

7 motor stalls and 1 battery issue. Seven of the patients with
pump failures had no symptoms and the pump failures were
identiﬁed after the pumps alarmed and / or during pump
reﬁll. As described above, there was one undetected pump
failure, which was adjudicated by the AEAC to have contributed to their death. Six of these seven surviving subjects
had their pump replaced and did not experience another
pump failure event. One patient was considered by the investigator to be too sick to have pump replacement surgery and
decided to have palliative-only care.
All failed pumps were returned to the manufacturer for
a biomedical engineering investigation and destructive forensic analysis. Causes of each of the pump failures were identiﬁed, which involved high battery resistance, shaft wear, and

holes in pump tubing. Design changes to the shaft wear and
battery failure modes have been implemented to mitigate
future issues. Investigation continues into the cause of the
holes in the pump tubing, which has only occurred in
pumps that were implanted for more than 51 months and
had more than 33 reﬁlls. The seven patients with pump failures had the IDS implanted for 4–5 years and had between
18,000 and 25,000 motor turns (Fig. 3). Notably the majority
of the patients with this range and follow-up duration and
number of motor turns did not experience a pump failure.
Of note, there is a correlation with longer duration of implant
and ﬂow rate (dose) with the number of motor turns.
Kaplan–Meier survivorship plots using catheter failure,
pump failure, pump replacement or pump explant without
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Fig. 4. Kaplan–Meier survivorship plots with 95% confidence limit error bars. (a) Five-year estimate from implant to catheter failure 94.3% (95%
CI 83.1–98.2%). (b) Five-year estimate from implant to pump failure 87.7% (95% CI 72.9–94.7%). (c) Five-year estimate from implant to pump
replacement or explanted without replacement 74.9% (95% CI 60.0–85.0%). (d) Five-year estimate from implant to system modification 69.8%
(95% CI 54.9–80.7%).

replacement, and system modiﬁcation as the events are provided (Fig. 4(a) to (d)). Five-year survival from catheter
failure was 94.3% and from pump failure was 87.7%.
Five-year survival from pump replacement or pump explant
without replacement was 74.9%, and survivorship from
system modiﬁcation was 69.8%.

Refill reactions
Throughout the study, patients had treprostinil-related reactions soon after their pump was reﬁlled, including local reactions near the pump reﬁll site such as pain, erythema, and
swelling and / or systemic reactions including ﬂushing, headache, nausea, and hypotension. Upon investigation of the
reﬁll procedure by the biomedical team, it was determined
that when the needle was pulled out through the skin a small
droplet of drug could be expelled from the needle opening

causing a local site reaction. The team also determined that
reﬁlling the pump with chilled drug would reduce the pressure in the pump reservoir thus limiting residual drug from
exiting the needle as it was withdrawn at the completion of
the reﬁll process.
The FDA approved the option to use chilled drug during
reﬁlls in December 2013. Since, treprostinil reﬁll site reactions have been signiﬁcantly reduced from 4% (42/1054)
when using non-chilled drug to 1.4% (20/1467) with chilled
drug (p value < 0.0001). Serious reﬁll reactions were also
signiﬁcantly reduced from 0.9% (10/1054) when using
non-chilled treprostinil compared to 0.1% (2/1467) with
chilled drug (p value ¼ 0.006). All AEs due to reﬁll reactions
resolved within 24–48 h. No subject had a pocket ﬁll, which
is deﬁned as an inadvertent injection of drug during reﬁll
directly into the subcutaneous tissue or the pump pocket
instead of into the pump.

6

| DelIVery for PAH

Gomberg-Maitland et al.
100%

% Survival from Pump Replacement or
Explant without Replacement

(c)

90%
80%

74.9%

70%
60%
50%
40%
30%
20%

Error bars represent 95%
confidence intervals

10%
0%
0

6

12

18

24

30

36

42

48

54

60

50

48

40

31

Months Since Implant
Number at risk
60

57

56

56

54

52

51

(d)

Fig. 4. Continued.

Adverse events
During the study follow-up period there were 340 AEs in the
60 subjects that were adjudicated as related to the system
and/or treprostinil. Forty-seven of those (13.8%) were adjudicated as serious. The majority were events commonly seen
after an invasive procedure (e.g. pain, swelling at procedure
site) or associated with treprostinil infusion (i.e. reﬁll reactions). Figure 5 shows the proportion of patients with an AE
during every six-month interval post-implant for the ﬁve
most common system and/or drug-related events. The rate
of AEs reduced over time except in the post-reﬁll reaction,
as expected.
Pump ﬂow rate accuracy: The ﬂow rate accuracy (deﬁned
as the actual delivered volume / programmed delivery
volume) of the IDS ﬁlled with treprostinil has been observed
to decrease over time.5 The decline in ﬂow rate accuracy was
observed by noting more residual drug in the reservoir than
expected at scheduled pump reﬁlls. The decline in ﬂow rate

accuracy correlated with the cumulative volume of drug
delivered, which is dependent on the ﬂow rate and implant
time / reﬁll number. Figure 6 shows the 95% tolerance interval of an exponential model of reﬁll accuracy versus reﬁll
number in the DelIVery for PAH trial. If during a pump
reﬁll, the accuracy ratio was calculated to be outside the
gray area of the graph in Fig. 6, clinicians were instructed
to up-titrate the programmed dose if medically necessary.
There were no serious clinical events related to ﬂow rate
accuracy. However, some patients clinically noted changes
in their functional status and required up-titration of dose
or change in their concomitant PAH therapies.

Discussion
Continuous IV prostacyclin infusion therapy for severe
PAH is eﬀective with signiﬁcant clinical data supporting
long-term use.1 It is often utilized late in patient care, and
often at very advanced stages of disease due to under-
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Fig. 5. Adverse event proportion over time for the five most common therapy related adverse events.

Fig. 6. Implantable system for remodulin expected accuracy ratio for
a 40-mL refill volume. The shaded area represents the DelIVery for
PAH clinical trial accuracy data (95/95% tolerance interval of the
exponential data model).

recognition of disease severity and because of its complex
delivery system and inherent safety concerns, particularly
related to the constant risk of life-threatening blood
stream infections (BSIs) associated with external pump
delivery.9 Successful initiation and use of parenteral prostacyclins require strong family/social support, compliance
with medication changes, and scrupulous catheter care.
Infection, as with any long-term indwelling central venous
catheter, can result in signiﬁcant morbidity and mortality
that has been reported in PAH patients treated with IV
prostacyclin therapy.4 Because the IDS is internally
implanted, the infection risks associated with external

systems are eliminated. In fact, the approved labeling comparison for BSI rates has a 44-fold reduction for the fully
implanted system compared to external systems (1 per 133
patient-years vs. 1 per 3 patient-years, respectively).8
The recent FDA approval 30 July 2018 (announced 31
July 2018 press release) of this IDS provides clinicians who
manage severe PAH access to an eﬀective therapy with a
markedly reduced risk of infections, including serious
BSIs, and oﬀers them the opportunity to utilize this therapy,
after initial stabilization of a patient on externally administered drug. Its use also oﬀers the ability for a patient to
live a near normal lifestyle without the limitations imparted
by the need for an external pump and infusion system.
This included showering, bathing, swimming and other
related activities, and limited the need for daily medication
preparation.
The risks associated with pump reservoir reﬁlls were mitigated by having reﬁlls performed at clinical trial centers with
well trained, experienced clinicians who were prepared to
manage the complications that could arise with inadvertent
injection or leakage of treprostinil into the subcutaneous
space surrounding the pump. Such device pocket injection
did not occur in any experience. Reﬁll reactions, manifested
as both local and systemic adverse eﬀects, were due to a
small amount of treprostinil being extruded from the reﬁll
needle during withdrawal.
Injecting chilled drug into the pump reservoir causes the
propellant surrounding the drug reservoir to condense to a
liquid state, which transiently lowers the reservoir pressure
below ambient. This causes any residual drug in the needle
to stay in the needle when it is withdrawn from the reservoir
and thereby decreases the frequency and severity of reﬁll
reactions. If the reservoir pressure is above ambient when
the needle is withdrawn from the reservoir, any residual
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drug in the needle may be expelled from the needle and
delivered into the subcutaneous tissue resulting in local
and potential systemic reactions.
After subjects experienced pump failure, the investigative
team sought to determine the etiology of these events. After
destructive forensic evaluation by the manufacturer, pump
design changes have been implemented that address many of
the observed pump failures and motor stalls. Recommended
management of an implanted pump includes periodic demonstration to the patient of the audible pump alarm to
assure prompt recognition of the alarm; telemetered interrogation and review of pump logs at all patient encounters,
including whenever a patient presents with an alarm or signiﬁcant change in their symptoms. The risks of early
prophylactic pump replacement need to be balanced against
the risks of mechanical pump failure. The risks of pump
replacement surgery include the inherent risk of anesthesia
in patients with severe PAH and the risk of peri-operative
infection. The risk of infection associated with this
abdominal wall surgical replacement of the pump during
the clinical trial was 12% (2/17), similar to Medtronic’s
unpublished data available from their product surveillance
registry of the SynchroMed II 40 mL pump used for intrathecal infusion applications, which estimates a pump
replacement infection rate of 7%.10
One safety measure that is recommended is programming
the pump to minimum rate mode and placing barriers
between exposed junctions during pump replacement. This
will limit the risk of drug leakage into the subcutaneous
tissues during pump replacement. The interruption of drug
delivery during pump replacement was for a short duration
so that external line delivery was not required but should be
quickly available if the procedure time is extended due to
unusual issues.
Collaborative teamwork with clinicians, patients, and
industry helped improve study outcomes during all phases
of the study. The investigative team: (1) developed better
surgical procedures to reduce the risk of catheter and
pump displacement and mitigate catheter migration over
the pump reﬁll port, (2) reﬁned the technique for pump reservoir reﬁlls to minimize the risk of local and systemic reﬁll
reactions, (3) quantiﬁed the reduction in pump ﬂow rate that
occurs over time based on the number of reﬁlls and dose
adjust, and (4) developed protocols to manage catheter,
pump, total system replacement, and peri-lung transplant
procedures. These processes and guidance required a collaborative relationship with academia and industry and
will help with the larger scale distribution of the system.
The IDS will require not just an expert PAH team but a
coordinated approach for each aspect of the care: evaluation, implantation, recovery, reﬁlls, emergency management, and replacement. The pump improved outcomes but
is not a simple trade-oﬀ for the external system.
Who is best suited for an implantable system? As in this
phase 1 study, the best suited patients are not WHO functional class 4, are able to tolerate the procedure itself, are

able to return to the treatment center for follow-up reﬁlls,
have prior experience with treprostinil, and did not require
frequent escalation of prostacyclin therapy. New risk stratiﬁcation guidelines1 aim for near clinical perfection such as,
patients are often WHO functional class 4 at the initiation of
parenteral prostacyclin therapy, which may be too late.9
Perhaps the availability of the IDS will encourage patients
and physicians to utilize IV therapy when, in the past, it was
not encouraged or wanted due to the permanent indwelling
IV and infection risk. The observed survival statistics are
similar to reported survival with prostacyclin therapy in historical PAH patients.

Limitations
A quality of life assessment tool was collected for each
patient, but only 12-months post-implant. The results of
this study cannot necessarily be extrapolated to real world
clinical practice as the study was performed in carefully
selected and highly experienced PAH centers. Some patients
may need adjustment of their dose based on the IDS pump
ﬂow rate changes experienced over time if associated with
changes in symptoms or other objective assessments of an
individual patient’s status, such as measured exercise capacity. A coordinated approach between the patient and
PAH expert team can minimize symptoms based on these
mechanistic changes. In addition, due to the pharmacologic
properties of other prostacyclin analogs (primarily lack of
long-term thermal stability) the system can currently only be
used with treprostinil for continuous IV infusion of prostacyclin therapy.

Conclusion
After more than 280 patient-years of experience, the fully
implanted treprostinil IV delivery system has been shown to
result in a signiﬁcant decrease in the risk of BSIs and catheter dislocations, and prevented catheter occlusions in PAH
patients, while providing patients enhanced day-to-day
living experience (swimming and bathing). As with all
implantable devices/systems, state-of-the art equipment,
and extensive medical and surgical experience are required
to minimize the risks of peri-operative infection, pocket ﬁlls
and reﬁll reactions and system malfunction. Our reported
experience will facilitate the implementation of this novel,
implantable IV delivery system into the PAH patient community with continued guidance and oversight.
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